Sei Investments Co. Has $1.13 Million Stock Holdings in Annexon, Inc. $ANNX

Sei Investments Co. lifted its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 248.8% during the first quarter, Holdings Channel reports. The firm owned 203,236 shares of the company’s stock after purchasing an additional 144,977 shares during the quarter. Sei Investments Co.’s holdings in Annexon were worth $1,126,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Annexon by 65.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after buying an additional 2,785 shares during the period. Landscape Capital Management L.L.C. acquired a new position in shares of Annexon in the fourth quarter worth about $50,000. CIBC Bancorp USA Inc. acquired a new position in shares of Annexon in the third quarter worth about $31,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Annexon in the fourth quarter worth approximately $52,000. Finally, Abel Hall LLC purchased a new position in shares of Annexon in the first quarter worth approximately $61,000.

Insider Transactions at Annexon

In related news, Director Muneer A. Satter bought 613,497 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was bought at an average price of $5.41 per share, for a total transaction of $3,319,018.77. Following the transaction, the director directly owned 10,342,134 shares in the company, valued at $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 10.31% of the stock is currently owned by insiders.

Annexon Price Performance

NASDAQ ANNX opened at $5.33 on Thursday. The company has a 50 day simple moving average of $5.35 and a 200-day simple moving average of $5.53. The firm has a market capitalization of $873.27 million, a price-to-earnings ratio of -4.37 and a beta of 1.18. Annexon, Inc. has a 52-week low of $2.03 and a 52-week high of $7.18.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). On average, analysts predict that Annexon, Inc. will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

ANNX has been the subject of several research analyst reports. Needham & Company LLC upped their price target on shares of Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research report on Friday, July 17th. Citizens Jmp started coverage on shares of Annexon in a research note on Tuesday, July 21st. They set a “market underperform” rating and a $3.00 target price on the stock. Wall Street Zen lowered Annexon from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Citigroup upgraded Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $15.33.

Trending Headlines about Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: Annexon reported encouraging early results from the FORWARD study of tanruprubart in Guillain-Barré syndrome, including rapid strength improvement and reduced disability. The company expects to submit a U.S. Biologics License Application in the fourth quarter of 2026, creating a significant near-term regulatory catalyst. Annexon second-quarter 2026 financial results and business updates
• Positive Sentiment: The company expanded the Phase 3 ARCHER II trial of vonaprument in geographic atrophy with a Month 24 dual-primary endpoint while retaining the Month 15 endpoint. Management said Month 15 results remain on track for the fourth quarter of 2026, potentially giving the program two independent opportunities to demonstrate vision-preserving efficacy. Annexon expands vonaprument Phase 3 program
• Positive Sentiment: A credit facility of up to $200 million, including $50 million drawn initially, is expected to extend Annexon’s cash runway into 2028. The company also expects proof-of-concept data for oral autoimmune-disease candidate ANX1502 in fall 2026.
• Neutral Sentiment: Unusually heavy options activity showed call purchases 244% above average, reflecting increased speculative interest but not necessarily a fundamental change in valuation or outlook.
• Negative Sentiment: Second-quarter adjusted results were weaker than expected: Annexon reported a loss of $0.28 per share versus the $0.23 consensus estimate. Net loss increased to $55.3 million from $49.2 million year over year, while research and development expenses rose to $46.6 million.
• Negative Sentiment: The added Month 24 ARCHER II endpoint extends the final trial timeline into the third quarter of 2027, potentially delaying definitive results and commercialization. The credit facility improves liquidity but also increases reliance on external capital and future financing.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.